Tamoxifen N-oxide (BioDeep_00000011253)
Secondary id: BioDeep_00001878001
human metabolite Endogenous blood metabolite
代谢物信息卡片
化学式: C26H29NO2 (387.2198)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 36.3%
分子结构信息
SMILES: CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCC[N+](C)(C)[O-])C3=CC=CC=C3
InChI: InChI=1S/C26H29NO2/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)29-20-19-27(2,3)28/h5-18H,4,19-20H2,1-3H3/b26-25-
描述信息
Tamoxifen N-oxide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
同义名列表
数据库引用编号
11 个数据库交叉引用编号
- ChEBI: CHEBI:63825
- KEGG: C16545
- PubChem: 3033895
- PubChem: 63060
- HMDB: HMDB0060513
- Metlin: METLIN710
- CAS: 75504-34-6
- PMhub: MS000025225
- PubChem: 51090874
- NIKKAJI: J365.967D
- KNApSAcK: 63825
分类词条
相关代谢途径
Reactome(4)
BioCyc(0)
PlantCyc(0)
代谢反应
52 个相关的代谢反应过程信息。
Reactome(50)
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
ATP + PROP-CoA + carbon dioxide ⟶ ADP + MEMA-CoA + Pi
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
ATP + PROP-CoA + carbon dioxide ⟶ ADP + MEMA-CoA + Pi
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- FMO oxidises nucleophiles:
H+ + MTZ + Oxygen + TPNH ⟶ H2O + MTZ-SOX + TPN
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(2)
- Tamoxifen Action Pathway:
4-Hydroxytamoxifen + Phosphoadenosine phosphosulfate ⟶ 4-Hydroxytamoxifen sulfate + Adenosine 3',5'-diphosphate
- Tamoxifen Metabolism Pathway:
4-Hydroxytamoxifen + Phosphoadenosine phosphosulfate ⟶ 4-Hydroxytamoxifen sulfate + Adenosine 3',5'-diphosphate
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Juan Peris-Vicente, Enrique Ochoa-Aranda, Devasish Bose, Josep Esteve-Romero. Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography.
Talanta.
2015 Jan; 131(?):535-40. doi:
10.1016/j.talanta.2014.07.093
. [PMID: 25281137] - Cécile Arellano, Ben Allal, Anwar Goubaa, Henri Roché, Etienne Chatelut. An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.
Journal of pharmaceutical and biomedical analysis.
2014 Nov; 100(?):254-261. doi:
10.1016/j.jpba.2014.07.033
. [PMID: 25173109] - Jennifer Gjerde, Sara Gandini, Aliana Guerrieri-Gonzaga, Line L Haugan Moi, Valentina Aristarco, Gunnar Mellgren, Andrea Decensi, Ernst A Lien. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.
Breast cancer research and treatment.
2012 Jul; 134(2):693-700. doi:
10.1007/s10549-012-2074-9
. [PMID: 22562123] - Malgorzata Jaremko, Yumi Kasai, Myra F Barginear, George Raptis, Robert J Desnick, Chunli Yu. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.
Analytical chemistry.
2010 Dec; 82(24):10186-93. doi:
10.1021/ac102337d
. [PMID: 21086978] - Jennifer Gjerde, Jürgen Geisler, Steinar Lundgren, Dagfinn Ekse, Jan Erik Varhaug, Gunnar Mellgren, Vidar M Steen, Ernst A Lien. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
BMC cancer.
2010 Jun; 10(?):313. doi:
10.1186/1471-2407-10-313
. [PMID: 20565970] - Monica Mazzarino, Xavier de la Torre, Roberto Di Santo, Ilaria Fiacco, Federica Rosi, Francesco Botrè. Mass spectrometric characterization of tamoxifene metabolites in human urine utilizing different scan parameters on liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM.
2010 Mar; 24(6):749-60. doi:
10.1002/rcm.4432
. [PMID: 20187079] - J Gjerde, E R Kisanga, M Hauglid, P I Holm, G Mellgren, E A Lien. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. A.
2005 Jul; 1082(1):6-14. doi:
10.1016/j.chroma.2005.01.004
. [PMID: 16038189] - S J Carter, X F Li, J R Mackey, S Modi, J Hanson, N J Dovichi. Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry.
Electrophoresis.
2001 Aug; 22(13):2730-6. doi:
10.1002/1522-2683(200108)22:13<2730::aid-elps2730>3.0.co;2-3
. [PMID: 11545399]